TheraSphere for liver cancer before market in Japan
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment called TheraSphere for people with liver cancer that hasn't responded to standard care or can't have it. TheraSphere uses tiny radioactive beads to target tumors in the liver, and this study is being done to get it approved in Japan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have liver cancer that is primary (started in the liver) or secondary (spread from elsewhere), as shown by a scan or biopsy
- Standard treatments have failed or you are not eligible for them, as decided by a team of doctors
- Your cancer is mostly in the liver, and you are expected to live at least 3 more months
- You are in good enough health to be up and around (able to care for yourself), with a score of 0 or 1 on a standard scale
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted internal radiation treatment for people with liver cancer (HCC) that is too widespread for surgery and goes beyond the up-to-7 criteria. It aims to see if this therapy can safely and effectively treat tumors that are all located in a specific area of the liver.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This study tests whether a targeted radiation treatment called Y-90 segmentectomy can shrink liver tumors. It is for people with one to three small liver tumors that cannot be removed by surgery or destroyed by heat or cold (ablation).
This trial tests an affordable, Indian-made treatment for liver cancer (HCC) that can't be surgically removed. Tiny beads (microspheres) are injected into the liver's blood supply to directly deliver radiation to the tumor, potentially shrinking it and slowing the cancer.
This study checks how well a custom radiation treatment plan works for people with a single liver tumor (HCC) that hasn't been treated before. TheraSphere uses tiny beads with radiation to target the tumor while sparing healthy liver.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
Hear when a new Liver Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.